Antiverse Ltd.. (3/1/23). "Press Release: Antiverse Raises Funding and Demonstrates Therapeutic Antibody Identification with AI-driven Drug Discovery platform". Cardiff.

	Organisation	Antiverse Ltd.
	Organisation 2	Development Bank of Wales (DBW)
	Group	Wales (govt)
	Product	AI-based drug discovery / AI-based drug development
	Product 2	venture capital
	Index term	Antiverse–SEVERAL: investment, 202303 seed financing round extension $3m from existing + new investors
	Person	Tunaboylu, Murat (Antiverse 202103 CEO + Co-Founder)
	Person 2	Pack, Peter (mtm laboratories 1999–200806 CEO + founder)

Seven human G-protein coupled receptor antibodies were characterised, showing high affinity and blocking function. $3 million USD investments will enable further development of these assets in-house.

[picture] Structural model showing the 7 functional GPCR binders overlapped. CDRH3 domains are highlighted in dark blue. These models were generated using Antiverse’s proprietary structural model prediction program ‘OrIgami’.

Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. The Company also announced that it has raised $3 million in funding, which will enable in-house development of the antibodies showing the highest affinity blocking function, making them ideal starting points as therapeutic assets.

The antibodies were identified using Antiverse’s proprietary computational antibody drug discovery platform, which uses machine learning to model antibody-antigen interactions and design de novo antibodies. The platform was used to identify a diverse set of binders to two structurally distinct GPCRs, and following Fluorescence-Activated Cell Sorting (FACS), 8 antibodies were identified as human GPCR binders (Figure 1). 7 of these binders were confirmed as antagonists (Figure 2), blocking GPCR activity.

Figure 1: FACS analysis of human GPCR expressing cell lines conjugated with antibody candidates. Data in blue represents specific binders, data in orange shows candidates which bound untransfected cells (non-specific binders), and data in grey shows non-binding controls.

Figure 2: Antagonistic assay of antibody candidates after 15 minutes, and 1 hour of incubation. hGPCR binders 2, 4, 8. 12, 13, 15 and 16 are hGPCR antagonists.

GPCRs are a class of cell membrane receptors that play a crucial role in various physiological processes. Due to their link to several pathologies and diseases and the fact that approximately half of all prescription drugs target the GPCR family, they are attractive targets for drug discovery campaigns. Diseases linked to GPCRs include diabetes, cardiovascular and psychiatric disorders. Despite these connections, very few biologic therapies have been developed for GPCRs, as they are notoriously challenging to generate antibodies against. With over 400 GPCRs linked to over 30 diseases, and only two FDA-approved antibody therapeutics existing for this family of receptors, these assets have significant potential for therapeutic applications.

The $3 million investment was received from new investors InnoSpark, AngelHub, Kadmos Capital and Tomorrow Scale, as well as existing investors, Tensor Ventures, Deep Science Ventures, Ed Parkinson and Development Bank of Wales (DBW).

Murat Tunaboylu, the co-founder and CEO of Antiverse said:

“This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators.”

Peter Pack, antibody engineer and NED added:

“Antiverse’s AI-powered methods to generate nanomolar binders against ‘difficult’ antigens such as GPCRs in silico is a game-changer in the antibody discovery industry, the most important innovation since the invention of phage display. We will see large savings in cost and time in the discovery and development of antibodies.”

Matt Fates, a board member at Antiverse and partner at InnoSpark commented:

“We see tremendous potential in the Antiverse platform. Their combination of AI-driven antibody design with proprietary laboratory validation shows great promise in targeting historically challenging GPCRs linked to cancer and a wide variety of other conditions. We congratulate the team on their achievement in the pursuit of bringing new treatments to patients."

To learn more about Antiverse and how we are engineering the future of drug discovery, you can visit our website antiverse.io and follow us on LinkedIn or Twitter.

Media Contact

Name: Luke Bateman
Title: Marketing Specialist and Business Development Lead
Email: [email protected]

About Antiverse

Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to curate diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.

Record changed: 2024-11-06